JP2017506626A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506626A5
JP2017506626A5 JP2016550471A JP2016550471A JP2017506626A5 JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5 JP 2016550471 A JP2016550471 A JP 2016550471A JP 2016550471 A JP2016550471 A JP 2016550471A JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015633 external-priority patent/WO2015123423A2/en
Publication of JP2017506626A publication Critical patent/JP2017506626A/ja
Publication of JP2017506626A5 publication Critical patent/JP2017506626A5/ja
Pending legal-status Critical Current

Links

JP2016550471A 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 Pending JP2017506626A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461939857P 2014-02-14 2014-02-14
US61/939,857 2014-02-14
US201462000162P 2014-05-19 2014-05-19
US62/000,162 2014-05-19
US201462025094P 2014-07-16 2014-07-16
US62/025,094 2014-07-16
US201462052227P 2014-09-18 2014-09-18
US62/052,227 2014-09-18
EP14306729.6 2014-10-29
EP14306729 2014-10-29
PCT/US2015/015633 WO2015123423A2 (en) 2014-02-14 2015-02-12 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy

Publications (2)

Publication Number Publication Date
JP2017506626A JP2017506626A (ja) 2017-03-09
JP2017506626A5 true JP2017506626A5 (OSRAM) 2018-03-15

Family

ID=51870958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550471A Pending JP2017506626A (ja) 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法

Country Status (10)

Country Link
US (2) US20150231236A1 (OSRAM)
EP (1) EP3104879A2 (OSRAM)
JP (1) JP2017506626A (OSRAM)
KR (1) KR20160115939A (OSRAM)
CN (1) CN106029096A (OSRAM)
AU (1) AU2015217118A1 (OSRAM)
CA (1) CA2939507A1 (OSRAM)
EA (1) EA201691320A1 (OSRAM)
MX (1) MX2016010504A (OSRAM)
WO (1) WO2015123423A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
HRP20180959T1 (hr) 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2848201C (en) 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20140257473A1 (en) * 2012-10-22 2014-09-11 Nalini Marie Rajamannan Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10058630B2 (en) 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN111920954A (zh) 2013-06-07 2020-11-13 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10689460B2 (en) * 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20230374155A1 (en) * 2014-05-15 2023-11-23 Rani Therapeutics, Llc Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
IL314925A (en) 2015-08-18 2024-10-01 Regeneron Pharma Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
EP3347050B1 (en) * 2015-09-08 2025-01-15 Rani Therapeutics, LLC Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10939164B2 (en) 2016-05-10 2021-03-02 Rovi Guides, Inc. Method and system for transferring an interactive feature to another device
EP3474780A4 (en) * 2016-06-27 2020-02-26 Concievalve LLC METHODS OF INHIBITING STENOSIS, OBSTRUCTING OR CALCIFYING A CARDIAC VALVE WITH STENT OR BIOPROSTHESIS
KR102401796B1 (ko) 2017-04-13 2022-05-25 카딜라 핼쓰캐어 리미티드 신규의 펩타이드 기재 pcsk9 백신
GB201720162D0 (en) 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
HRP20180959T1 (hr) * 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
CA2848201C (en) * 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
NZ702093A (en) * 2012-05-25 2017-08-25 Catabasis Pharmaceuticals Inc Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)

Similar Documents

Publication Publication Date Title
JP2017506626A5 (OSRAM)
JP2017528427A5 (OSRAM)
JP7404471B2 (ja) 家族性高コレステロール血症を有する患者を処置するための方法
JP2016538248A5 (OSRAM)
JP2016538277A5 (OSRAM)
JP2022141868A (ja) 心血管リスクを低減させる方法
JP2016522211A5 (OSRAM)
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP2017522316A5 (OSRAM)
Bertrand et al. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
JP2020002171A5 (OSRAM)
JP2019514907A5 (OSRAM)
JP2017509624A5 (OSRAM)
JP2016520616A5 (OSRAM)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2022177142A5 (OSRAM)
RU2017104800A (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
JP2017503820A5 (OSRAM)
RU2017104799A (ru) Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
JP2018523684A5 (OSRAM)
JP2016529255A5 (OSRAM)
JP2014516953A5 (OSRAM)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP7541810B2 (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP2020504110A5 (OSRAM)